Colon Cancer Clinical Trial

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Summary

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

View Full Description

Full Description

RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS inhibitor. RSC-101 is a Phase 1a/1b, open-label, multi-center, non-randomized, Dose Escalation and Dose Expansion study in participants with advanced solid tumor malignancies. Study enrollment is approximately 134 participants. All participants receive oral RSC-1255, twice daily as monotherapy. Following Phase 1a (Dose Escalation) to identify the Maximum Tolerated Dose and Recommended Dose for use in Phase 1b, additional participants are enrolled in the Phase 1b (Dose Expansion) to further characterize the safety, pharmacology, and the clinical efficacy of RSC-1255.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria (Key Factors):

Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:

Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
Malignancy has progressed on standard therapy
Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and/or laboratory assessments as applicable to their malignancy.
Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).
Is age ≥ 18 years.

Exclusion Criteria (Key Factors):

Participants receiving cancer therapy at the time of enrollment.
Any clinically significant disease or condition affecting a major organ system.
Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.
Known Gilbert's disease.
Has had a previous (within 2 years) or has a current malignancy other than the target cancer.

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

134

Study ID:

NCT04678648

Recruitment Status:

Recruiting

Sponsor:

RasCal Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles California, 90404, United States
UC Davis Comprehensive Cancer Center
Sacramento California, 95817, United States
Anschutz Cancer Pavilion - University of Colorado Hospital
Aurora Colorado, 80045, United States
Sarah Cannon Research Institute - Health One
Denver Colorado, 80218, United States
Sidney Kimmel Cancer Center - Thomas Jefferson Hospital
Philadelphia Pennsylvania, 19107, United States
Sarah Cannon Tennessee Oncology
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Phase:

Phase 1

Estimated Enrollment:

134

Study ID:

NCT04678648

Recruitment Status:

Recruiting

Sponsor:


RasCal Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.